

ASX Release

Appendix 4C – Q3 2025 Quarterly Cash Flow Report

30 October 2025 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 30 September 2025 (Q3 25) and provided an update on business activities.

Financial Highlights

Oneview's cash balance at 30 September 2025 was €5.9 million (A\$10.5m) compared to €8.2 million (A\$14.7m) at 30 June 2025.

The Company had a net cash outflow of €2.2 million during the quarter compared to an outflow of €1.2 million in the same quarter of the prior year. Q3 25 was negatively impacted by the delayed receipt of an annual customer renewal fee of US\$2.01 million (approximately €1.7m / A\$3.1m) that was due in the quarter but not received until 21 October 2025. The same customer's prior year renewal fee of US\$1.67m (approximately €1.5m / A\$2.4m) was received during the third quarter of 2024.

Key components of the operating cash outflow in the quarter comprised:

- Receipts from customers totalled €2.7m (A\$4.8m), a decrease of €1.0 million on the prior year corresponding period due to the timing of receipts as noted above.
- Payments in respect of staff costs of €2.8m (A\$5.0m) were 5% lower than the prior year corresponding period. The decrease in staff costs reflects the initial benefits from the business restructuring executed in June 2025.
- Admin and corporate costs of €1.0 million (A\$1.9m) were slightly higher than the prior year corresponding period costs of €0.9 million (A\$1.5m) due to some cost inflation in software fees and the timing of outflows.

The Company's current cash balance is €6.7m (A\$11.9m) (as at 29 October 2025). The net inflow of €0.8 million since 30 September 2025 is due to strong customer receipt inflows during October 2025 to date, partially offset by operating outflows.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €171,000 (A\$306,000).

Operational Activities

Sales and Customer Updates

The Company maintained strong commercial momentum during the third quarter of 2025 and added another new customer logo, Kennedy Krieger. This leading Baltimore-based paediatric hospital and research centre is affiliated with Johns Hopkins, and specializes in treating neurological, developmental, and rehabilitative disorders and operates a 70-bed inpatient facility serving children and adolescents nationwide.

Oneview is also in advanced contract discussions with several prospective customers and expects to secure additional new customer logos before year-end.

The Company deployed approximately 850 endpoints during Q3 2025 and is on track to exceed 15,000 total live endpoints by the end of 2025.

Implementation projects progressed at our existing customer sites, including:

- Over 500 endpoints were deployed in the new BJC Plaza West Tower at the Washington University Medical Campus in St. Louis, Missouri.
- Deployments of the core platform, the digital door sign and the digital whiteboard continued during the third quarter of 2025 at Inova Health under the 1,900-bed Master Services Agreement which was signed in April 2024, with deployments at Inova Fairfax and Inova Fair Oaks Hospital Innovation Unit.
- The core platform and digital door sign were also deployed at Summit Pacific in Elma, Washington and deployments continued at the University of Miami.

Outlook

The Company maintained its solid commercial momentum and deployment progress during the third quarter of the year. Our strong U.S. pipeline of over 180 opportunities continues to deliver, with another new U.S. customer logo win and advanced contract negotiations underway with several prospects.

We continued to make progress on improving deployment speed and efficiency, with 850 endpoints rolled out during the quarter.

We look forward to closing out the year strongly by continuing the conversion of contracted endpoints to live, revenue-generating endpoints, while sustaining our commercial momentum through new customer acquisitions and account expansions to position the Company for continued growth into 2026.

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading

healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : www.oneviewhealthcare.com

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

30th September 2025

Consolidated statement of cash flows		Current quarter €'000	Year to date (9 months) €'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	2,710	9,075
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(1,006)	(3,818)
	(c) advertising and marketing	(65)	(199)
	(d) leased assets	-	-
	(e) staff costs	(2,819)	(9,027)
	(f) administration and corporate costs	(1,047)	(3,181)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	8	21
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes (paid)/refunded	-	(1)
1.7	Government grants and tax incentives	-	444
1.8	Other (working capital movements)	6	(589)
1.9	Net cash from / (used in) operating activities	(2,213)	(7,274)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(42)	(58)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(42)	(58)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	8,191	13,833
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(2,213)	(7,274)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(42)	(58)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(40)	(605)
4.6	Cash and cash equivalents at end of period	5,896	5,896

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	5,896	8,191
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,896	8,191

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	171
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,213)
8.2 Cash and cash equivalents at quarter end (item 4.6)	5,896
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	5,896
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.66
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:30 October 2025.....

Authorised by: **BY THE BOARD**
(Name of body or officer authorising release – see note 4)

Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.